Effect of Nintedanib on Lung Function in Patients With Systemic Sclerosis-Associated Interstitial Lung Disease: Further Analyses of a Randomized, Double-Blind, Placebo-Controlled Trial.
Toby M MaherMaureen D MayesMichael KreuterElizabeth R VolkmannMartin AringerIvan CastellviMaurizio CutoloChristian StockNils SchoofMargarida AlvesGanesh Raghunull nullPublished in: Arthritis & rheumatology (Hoboken, N.J.) (2021)
These results suggest that nintedanib has a clinically relevant benefit on the progression of SSc-ILD.